Published in Women's Health Weekly, July 27th, 2006
Bazedoxifene is a selective estrogen receptor modulator (SERM).
According to the U.S. National Osteoporosis Foundation, as of 2002 8 million American women have osteoporosis and almost 27 million women are estimated to have osteopenia (low bone mass), placing them at increased risk for osteoporosis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.